文献速递妇科产科

绝经后出血妇女子宫内膜癌诊断中活检策略的成本效益分析:Pipelle取样刮匙与刮宫术比较

Cost-effectiveness analysis of biopsy strategies for endometrial cancer diagnosis in women with postmenopausal bleeding: Pipelle sampling curette versus dilatation & curettage.
PubMed 文献 · Gynecol Oncol · 2018-05-07

该决策分析模型从美国公共医疗支付方(Medicare)角度,比较Pipelle子宫内膜取样与刮宫术(D&C)在绝经后出血(PMB)女性中诊断子宫内膜癌(EC)的成本效益。基础分析显示Pipelle与D&C效果相等(32.11年对32.11年生命年),但Pipelle费用更低(1897.80美元对2999.11美元)。单因素敏感性分析和蒙特卡洛概率敏感性分析中,Pipelle仍为更具成本效益的取样策略。

要点

  • Pipelle与D&C在诊断EC后的剩余预期寿命相等,均为32.11年。
  • Pipelle的Medicare报销费用低于D&C(1897.80美元对2999.11美元)。
  • 敏感性分析中Pipelle仍为更具成本效益的取样策略。

核心结论

  • 对于PMB女性EC诊断,Pipelle是比D&C更具成本效益的取样策略。
  • 从成本效益角度,Pipelle较高的取样失败率不应被视为其临床应用的局限。

研究设计与样本

  • 决策分析模型,在假设的PMB女性队列中比较Pipelle与D&C策略的成本效益。
  • 分析从美国公共医疗支付方(Medicare)角度进行,成本估算使用2017年Medicare报销数据。
  • 效果通过分析EC诊断及后续治疗后的剩余预期寿命衡量。

主要发现

  • 基础分析显示Pipelle与D&C效果相等(32.11年对32.11年生命年)。
  • Pipelle费用低于D&C(1897.80美元对2999.11美元,基于Medicare报销)。
  • 单因素敏感性分析和蒙特卡洛概率敏感性分析中,即使考虑各取样策略的取样失败率,Pipelle仍为更具成本效益的取样策略。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endometrial sampling is widely used for accurate diagnosis of endometrial cancer (EC), which is the most common gynecologic cancer in US women. The objective of this study was to explore the cost-effectiveness of two endometrial sampling procedures for diagnosing EC: (1) Pipelle endometrial sampling (Pipelle), and (2) dilatation & curettage (D&C), while accounting for sampling procedure failure rates and diagnostic accuracy in women with postmenopausal bleeding (PMB). METHOD: The decision analytic model was built to compare the cost-effectiveness of Pipelle and D&C strategies in a hypothetical cohort of PMB women. The analysis was performed from the perspective of a public healthcare payer (Medicare, US). We used 2017 Medicare reimbursement data for cost estimation. The effectiveness of these two diagnostic strategies was measured by analyzing the remaining life expectancy after EC diagnosis and subsequent treatment. RESULTS: The base case analysis suggested that Pipelle was not only equally effective (32.11 vs. 32.11 years of life), but also less costly ($1897.80 vs. $2999.11) based on Medicare reimbursement when compared to D&C. In one-way sensitivity analyses and Monte Carlo probabilistic sensitivity analysis, the Pipelle remained the more cost-effective sampling strategy even after accounting for sampling failure rate associated with each sampling strategy. CONCLUSION: The Pipelle is the more cost-effective sampling strategy compared to D&C for EC diagnosis in women with PMB. From the cost-effectiveness perspective, the higher sampling failure rate of Pipelle should not be regarded as a limitation in its clinical application.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Yi Y, Bryce CL, Adambekov S, et al. Cost-effectiveness analysis of biopsy strategies for endometrial cancer diagnosis in women with postmenopausal bleeding: Pipelle sampling curette versus dilatation & curettage. Gynecol Oncol. 2018. PMID: 29747864. doi:10.1016/j.ygyno.2018.04.565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。